Treatment as prevention

Texas Health Action to 'Rock the Ribbon' and offer free HIV testing on World AIDS Day

Retrieved on: 
Tuesday, November 15, 2022
People, Texas Department of State Health Services, Face, DSHS, Woman, Patient, Awareness, Post-exposure prophylaxis, PEP, Judgement, THA, Man, Cedar Springs Road, HIV, Education, Pre-exposure prophylaxis, Black, CEO, Walgreens, Texas Health and Human Services Commission, Health minister, Color, Diagnosis, Health, Treatment as prevention, Viral load, Pharmaceutical industry, Medical device, Communications satellite, Health insurance, Central Texas, Ribbon

AUSTIN, Texas, Nov. 15, 2022 /PRNewswire/ -- Texas Health Action—a community-informed nonprofit that provides access to quality health services in a safe and supportive environment—will provide free HIV testing beginning on World AIDS Day, December 1, 2022, at Kind Clinic locations in Austin, Dallas and San Antonio. Texas Health Action's HIV initiative, "Rock the Ribbon," is meant to raise awareness of HIV through free walk-in testing and community engagement. Anyone is eligible for free testing, regardless of immigration status or ability to pay. No appointment is required.

Key Points: 
  • Kind Clinic to offer free walk-in testing in Austin, Dallas and San Antonio
    AUSTIN, Texas, Nov. 15, 2022 /PRNewswire/ --Texas Health Actiona community-informed nonprofit that provides access to quality health services in a safe and supportive environmentwill provide free HIV testing beginning on World AIDS Day, December 1, 2022, at Kind Clinic locations in Austin, Dallas and San Antonio.
  • Texas Health Action's HIV initiative, "Rock the Ribbon," is meant to raise awareness of HIV through free walk-in testing and community engagement.
  • "While the red ribbon is the universal symbol of awareness and support for people living with HIV, Texas Health Action's 'Rock the Ribbon' empowers Texans to know their HIV status," Christopher Hamilton, CEO of Texas Health Action, said.
  • In addition to HIV testing, Kind Clinic offers HIV care, access to the HIV prevention medication PrEP (pre-exposure prophylaxis) and PEP (post-exposure prophylaxis).

Ansell Adopts Exabeam Fusion for Threat Detection, Investigation, and Response

Retrieved on: 
Friday, November 4, 2022
Technology, Medical Supplies, Finance, Security, Other Technology, Professional Services, Other Health, Data Analytics, Health, Data Management, EMEA, Health care, XDR, Workflow, Treatment as prevention, Cisco Security Monitoring, Analysis, and Response System, Cisco Systems, Behavior, Automation, CEO, Organization, Socs, Ansell, Health, Technology, PPE, Solution, Risk management, Online shopping, SIEM, Asia-Pacific

Exabeam , a global cybersecurity leader and creator of New-Scale SIEM for advancing security operations, announced today that Ansell has adopted Exabeam Fusion security information and event management (SIEM) across its U.S. locations and offices.

Key Points: 
  • Exabeam , a global cybersecurity leader and creator of New-Scale SIEM for advancing security operations, announced today that Ansell has adopted Exabeam Fusion security information and event management (SIEM) across its U.S. locations and offices.
  • We are proud to provide Exabeam Fusion to protect a world leader in PPE manufacturing that, in turn, protects millions of workers around the world, said Michael DeCesare, CEO and president, Exabeam.
  • Ansell also showcases the immediate benefits our SIEM customers receive from our hundreds of integrations with the worlds leading IT and security products.
  • For more information about Ansell visit www.ansell.com
    Exabeam, the Exabeam logo, New-Scale SIEM, Detect the Undetectable, Exabeam Fusion, Smart Timelines, Exabeam Security Operations Platform, and XDR Alliance are service marks, trademarks, or registered marks of Exabeam, Inc. in the United States and other countries.

Exabeam Introduces New-Scale SIEM™

Retrieved on: 
Monday, October 17, 2022
Technology, Mobile, Wireless, Security, Professional Services, Software, Networks, Internet, Data Analytics, Data Management, Cloud, St Patrick's Industrial School, Upton, Time, Treatment as prevention, ERP, General manager, Organization, GA, Business intelligence, NASDAQ, Intelligence, Case management, National service, Google, Technology, Compliance, Automation, Solution, Radical behaviorism, Industry, Tag cloud, Behavior, Google Cloud, CEO, XDR, NEC, Environment, Verizon Communications, Risk management, Video game console, Medical device, SIEM

The SIEM industry has been ripe for evolution for some time and New-Scale SIEM represents that evolution.

Key Points: 
  • The SIEM industry has been ripe for evolution for some time and New-Scale SIEM represents that evolution.
  • Todays announcement takes Exabeam, our customers, partners, and the SIEM market into an entirely new stratosphere, said Ralph Pisani, President, Exabeam.
  • Exabeam SIEM - Cloud-native SIEM at hyperscale with fast, modern search, and powerful correlation, reporting, dashboarding, and case management.
  • Exabeam, the Exabeam logo, New-Scale SIEM, Detect the Undetectable, Exabeam Fusion, Smart Timelines, Exabeam Security Operations Platform, and XDR Alliance are service marks, trademarks, or registered marks of Exabeam, Inc. in the United States and other countries.

Forty Years on From the Start of the HIV Epidemic, New Data Reveals People Living With HIV Face Outdated Attitudes and Ongoing Discrimination

Retrieved on: 
Wednesday, December 1, 2021
Research, LGBTQ+, Pharmaceutical, Consumer, Technology, Infectious Diseases, Clinical Trials, Science, Biotechnology, AIDS, Other Technology, Health, Other Science, Prejudice, CEO, ARV, Probability, Calm (company), GlaxoSmithKline, Annual report, Health care, Company, PicMonkey, ViiV Healthcare, NYSE, Music, Health, Bias, LSE, COVID-19, Partner (business rank), GSK, Family, HIV-positive people, Hope, TurboSquid, 3D, AIDS, Risk, Collection, The Harris Poll, Treatment as prevention, Friends, Shionogi, PFE, Multimedia, Internal communications, Stratos Global Corporation, RED, HIV, Quality of life, Pharmaceutical industry, Vaccine, Video game

HIV in View features empowering images that authentically portray the reality of living with HIV today.

Key Points: 
  • HIV in View features empowering images that authentically portray the reality of living with HIV today.
  • Far from reflecting the fear once associated with HIV, the gallery is filled with inspiring examples of just how much things have changed for many people living with HIV.
  • I am proud to have taken part in the HIV in View photography project, to show that people living with HIV can live fulfilling, healthy lives.
  • I hope HIV in View helps people to understand the reality of living with HIV and removes HIV-related prejudice seen in the survey results.

AHF Commends the Resumption of HIV Treatment in Kenya – But More Is Needed

Retrieved on: 
Monday, July 26, 2021
Research, General Health, Pharmaceutical, White House, Federal Government, Infectious diseases, Public policy, Other Policy Issues, Science, Biotechnology, AIDS, Health, Public policy, Government, Medical specialties, HIV/AIDS, Health, Clinical medicine, Pandemics, Hepatotoxins, Sexually transmitted diseases and infections, Viral load, HIV, Treatment as prevention, HIV and pregnancy

As a result, distribution of lifesaving HIV/AIDS prevention and treatment medications has resumed as of July 14, according to the US Embassy.

Key Points: 
  • As a result, distribution of lifesaving HIV/AIDS prevention and treatment medications has resumed as of July 14, according to the US Embassy.
  • The damage done to peoples lives and wellbeingparticularly childrens livesis irreversible and must never be repeated.
  • Ensure that HIV management is implemented holistically by taking into consideration prevention and diagnosis, care and treatment, and related essential commodities, including medications.
  • This is urgently needed to address current shortages of paediatric HIV treatment, viral load testing reagents, and HIV test kits.

HIV is turning gray: Will the Biden White House Accept the Challenge?

Retrieved on: 
Friday, December 18, 2020
Medical specialties, Retroviridae, Hepatotoxins, Sexually transmitted diseases and infections, Articles, Management of HIV/AIDS, HIV/AIDS, HIV, Treatment as prevention, AIDS service organization

Some years later, the human immunodeficiency virus (HIV) caused AIDS was discovered, and it started the dark legacy that lives on today.

Key Points: 
  • Some years later, the human immunodeficiency virus (HIV) caused AIDS was discovered, and it started the dark legacy that lives on today.
  • Significant advances in care and treatment mean people with HIV are living longer.
  • In the U.S. today, young adults with HIV-infection who adhere to their antiretroviral treatment maintain lower viral loads and live longer.
  • Older HIV patients struggle to cope with many obstacles among them mental health problems, homelessness, and co-morbidities daily.

ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV

Retrieved on: 
Friday, October 16, 2020
Research, Infectious diseases, Clinical trials, Biotechnology, AIDS, Health, Pharmaceutical, Other Science, Science, Clinical medicine, Medicine, Prevention of HIV/AIDS, Health, Pre-exposure prophylaxis, RTT, HIV/AIDS, Hepatitis, Treatment as prevention, HIV and pregnancy, cabotegravir, rilpivirine and rilpivirine long-acting, ViiV Healthcare, GSK

Were proud to be providing different treatment options that meet the diverse needs of the HIV community.

Key Points: 
  • Were proud to be providing different treatment options that meet the diverse needs of the HIV community.
  • This treatment will offer people living with HIV an option with significantly less frequent dosing and comparable efficacy to daily oral regimens.
  • Cabotegravir is an INI developed by ViiV Healthcare for the treatment of HIV-1 in virologically suppressed adults.
  • Physicians should refer to current treatment guidelines for the management of HIV infection in patients co-infected with hepatitis B virus.

FDA Approves American Gene Technologies (AGT) to Move Forward with Phase 1 Clinical Trial of HIV Cure Program

Retrieved on: 
Tuesday, August 11, 2020
Branches of biology, Biology, Articles, Gene delivery, HIV/AIDS, Gene therapy, Viral vector, Surrogate endpoint, HIV, HIV vaccine, Treatment as prevention

AGTs Phase 1 trial will investigate the safety of AGT103-T, measure key biomarkers and explore surrogate markers of efficacy.

Key Points: 
  • AGTs Phase 1 trial will investigate the safety of AGT103-T, measure key biomarkers and explore surrogate markers of efficacy.
  • AGT103-T is a single-dose, lentiviral vector-based gene therapy developed to eliminate HIV from the millions of people globally infected with the disease.
  • Globally, nearly 38 million people have been infected with HIV and over one million people in the United States are living with HIV.
  • Our clinical trial sites in the metro area will test our new treatment in populations hardest hit by HIV.

ViiV Healthcare announces FDA approval of an expanded indication for Dovato (dolutegravir/lamivudine), a complete two-drug regimen for virologically suppressed adults with HIV-1

Retrieved on: 
Thursday, August 6, 2020
AIDS, FDA, Health, Clinical trials, Pharmaceutical, Biotechnology, Prevention of HIV/AIDS, GlaxoSmithKline, Pfizer, ViiV Healthcare, Treatment as prevention, HIV/AIDS, Dovato (dolutegravir/lamivudine), TANGO, ViiV Healthcare, GSK

At ViiV Healthcare, weve proven that with Dovato, adults living with HIV can reduce the number of ARVs they take every day without compromising efficacy or barrier to resistance.

Key Points: 
  • At ViiV Healthcare, weve proven that with Dovato, adults living with HIV can reduce the number of ARVs they take every day without compromising efficacy or barrier to resistance.
  • The approval of Dovato in adults who are virologically suppressed is based on the Week 48 results from the phase III TANGO study.
  • No participants on Dovato and one participant (
  • Dovato is approved for the treatment of HIV-1 in treatment-nave and virologically suppressed adults by the European Medicines Agency and additional regulatory authorities around the world.

FDA Approves New HIV Treatment for Patients With Limited Treatment Options

Retrieved on: 
Thursday, July 2, 2020
Medical specialties, Viruses, Retroviridae, Hepatotoxins, Management of HIV/AIDS, Sexually transmitted diseases and infections, Treatment as prevention, HIV/AIDS, HIV, Antiviral drug, HIV vaccine, Prevention of HIV/AIDS

"This approval marks a new class of antiretroviral medications that may benefit patients who have run out of HIV treatment options," said Jeff Murray, M.D., deputy director of the Division of Antivirals in the FDA's Center for Drug Evaluation and Research.

Key Points: 
  • "This approval marks a new class of antiretroviral medications that may benefit patients who have run out of HIV treatment options," said Jeff Murray, M.D., deputy director of the Division of Antivirals in the FDA's Center for Drug Evaluation and Research.
  • "The availability of new classes of antiretroviral drugs is critical for heavily treatment-experienced patients living with multidrug resistant HIV infectionhelping people living with hard-to-treat HIV who are at greater risk for HIV-related complications, to potentially live longer, healthier lives."
  • Most participants had been treated for HIV for more than 15 years (71 percent), had been exposed to five or more different HIV treatment regimens before entering the trial (85 percent) and/or had a history of AIDS (86 percent).
  • After 24 weeks of Rukobia plus other antiretroviral drugs, 53 percent of participants achieved HIV RNA suppression, where levels of HIV were low enough to be considered undetectable.